Mori K., Inatomi S., Ouchi K., Azumi Y., Tuchida T. Improving effects of the mushroom Yamabushitake (Hericium erinaceus) on mild cognitive impairment: a double-blind placebo-controlled clinical trial. Phytother Res. 2009;23(3):367–372.
Rationale
Mild cognitive impairment (MCI) carries an elevated risk of conversion to dementia, and no approved pharmacological intervention exists for it. Against preclinical evidence of neurotrophic action by H. erinaceus components (notably stimulation of nerve-growth-factor synthesis) and observations of cognitive effects in elderly patients in Japanese clinical practice, the authors asked whether prolonged oral intake of fruiting-body powder improves cognitive scores in diagnosed MCI.
Methods
Design — double-blind placebo-controlled RCT with parallel groups. Population — Japanese adults aged 50–80 with MCI. After a 2-week screening, 30 patients were randomized into two groups of 15: active received the mushroom, control received placebo. Intervention — four 250 mg tablets of 96% dry Yamabushitake fruiting-body powder (3 g/day) three times daily for 16 weeks; participants were observed for 4 more weeks after stopping. The primary endpoint was change on the Revised Hasegawa Dementia Scale (HDS-R), assessed at weeks 8, 12 and 16 and at week 4 post-discontinuation. Safety labs were also run.
Results
All 15 per group were analyzed. At weeks 8, 12 and 16 the mushroom group showed significantly increased HDS-R scores versus placebo, rising with intake duration. But by week 4 after discontinuation (study week 20) scores had significantly declined — the effect is reversible once intake stops. Laboratory tests found no adverse events attributable to the mushroom — no biochemical or hematological changes ascribable to the intervention. The annotation does not give exact mean HDS-R scores, absolute p-values or confidence intervals.
Conclusions
The authors conclude Yamabushitake (Hericium erinaceus) is effective for improving mild cognitive impairment — emphasizing that the effect builds gradually, depends on intake duration, and fades after discontinuation, implying continued intake is needed to sustain it.
Worth noting
This is one of the most-cited human clinical studies of lion's mane — and simultaneously one of the most modest in size: n=30 (15 per arm) is too small for firm efficacy conclusions, and the abstract omits exact HDS-R means, confidence intervals and per-visit p-values. The intervention is whole dried fruiting-body powder at 96% purity, not a standardized extract; other lion's mane studies use alcohol and water extracts with different active-compound profiles (hericenones, erinacines, β-glucans), so direct transfer to commercial extracts is improper. The work was done with explicit affiliation between the research center and the manufacturer (Hokuto Corporation) — a possible systematic bias, especially with a subjective behavioral scale. Finally, participants were Japanese aged 50–80 with diagnosed MCI; the effect cannot be transferred to healthy young people, other ethnic backgrounds or severe dementia. Replication on a larger, more diverse sample with modern neuropsychological scales (MoCA, ADAS-Cog) remains necessary.